GPT and ocular melanoma: The CR median duration of OM in these patients was 9.4 months, and 52% of the responders were free of the disease for 12 months; these values are lower than that observed for ALT-803 (26.6 months and 96% after 24 months) and pembrolizumab (16.2 months and 83% after 12 months).